Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.32 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26842631 | 0.94 | AR (0.32) | MAPK14ALDH1A1SMN1; SMN2MAPTLMNA | |
| SCHEMBL24483838 | 0.93 | HDAC1 (0.35) | ALDH1A1MAPTLMNAPARP1P2RX7 | |
| SCHEMBL22830553 | 0.93 | NTRK1 (0.35) | MAPK14ALDH1A1SMN1; SMN2PARP1 | |
| SCHEMBL22830558 | 0.92 | HDAC1 (0.31) | ALDH1A1LMNA | |
| SCHEMBL22845448 | 0.92 | MAPT (0.39) | ALDH1A1SMN1; SMN2MAPTLMNA | |
| SCHEMBL22717403 | 0.91 | AR (0.35) | PRKAA2 | |
| SCHEMBL24483837 | 0.91 | GCGR (0.38) | MAPT | |
| SCHEMBL22845527 | 0.91 | PREP (0.37) | MAPK14NR3C1SMN1; SMN2MAPTLMNA | |
| SCHEMBL22845442 | 0.91 | GRM5 (0.34) | MAPK14NR3C1ALDH1A1SMN1; SMN2PRKAA2 | |
| SCHEMBL24484060 | 0.89 | AURKA (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820773-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-11820773-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| WO-2022115384-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2022-06-02 | — | — | WO | disclosed |
| US-20220000874-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2022-01-06 | — | — | US | disclosed |
| US-11136321-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| US-20200407361-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2020-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220000874-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | MAPK14 1682/4885NR3C1 1318/4885ALDH1A1 648/4885 |
| US-11136321-B2 | Tricyclic compounds | SLC10A1, PKD1, CEL | MAPK14 1682/4885NR3C1 1318/4885ALDH1A1 648/4885 |
| US-11820773-B2 | Tricyclic compounds | SLC10A1, PKD1, CEL | MAPK14 1682/4885NR3C1 1318/4885ALDH1A1 648/4885 |
| US-20200407361-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | MAPK14 1682/4885NR3C1 1318/4885ALDH1A1 648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.